Coleman et al. identify a robust gene regulatory network for patients with FLT3-ITD AML, highlighting a crucial role of several different transcription factors including RUNX1 in FLT3-ITD pathology and identifying drug-responsive AML-subtype-specific and overlapping regulatory modules. Here, FLT3 is linked to acute myeloid leukemia.